Osteoporosis in Men: Insights for the Clinician

Therapeutic Advances in Musculoskeletal Disease

Volumn 3, Issue 4, 2011, Pages 191-200

  Adler, Robert A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

bisphosphonates; denosumab; dual energy X ray absorptiometry; fracture; men; osteoporosis; teriparatide; testosterone

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; STRONTIUM RANELATE; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

AGE; ALCOHOL ABUSE; ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DIZZINESS; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; JAW OSTEONECROSIS; KNOWLEDGE BASE; LABORATORY TEST; LEG CRAMP; LIFE EXPECTANCY; MALABSORPTION; MEDICAL HISTORY; OSTEOPENIA; OSTEOPOROSIS; PEPTIC ULCER; PHYSICAL EXAMINATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; SCREENING TEST; SMOKING; TESTOSTERONE BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 84857497207     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X11411600     Document Type: Review

References (69)

1. Abrahamsen B. (2010) Adverse effects of bisphosphonates. Calcif Tissue Int 86: 421–435
2. Adler R.A. (2011) Osteoporosis in prostate disease. Curr Med Lit Rheumatol 30: 1–7.
3. Adler R.A. Hastings F.W. Petkov V.I. (2010) Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAXTM. Osteoporos Int 21: 647–653.
4. Amory J.K. Watts N.B. Easley K.A. Sutton P.R. Anawalt B.D. Matsumoto A.M. et al (2004) Exogenous testosterone or testosterone plus finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89: 503–510.
5. Antoniucci D.M. Vittinghoff E. Palermo L. Black D.M. Sellmeyer D.E. (2009) Vitamin D does not affect response of bone mineral density to alendronate. Osteoporos Int 20: 1259–1266.
6. Baim S. Binkley N. Bilezikian J.P. Kendler D.L. Hans D.B. Lewiecki E.M. et al (2008) Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD position development conference. J Clin Densitom 11: 75–91.
7. Bartalena T. Rinaldi M.F. Modolon C. Braccaioli L. Sverzellati N. Rossi G. et al (2010) Incidental vertebral compression fractures in imaging studies: Lessons not learned by radiologists. World J Radiol 28: 399–404.
8. Bass E. French D.D. Bradham D.D. Rubenstein L.Z. (2007) Risk adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol 17: 514–519.
9. Behre H.M. Kliesch S. Leifke E. Link T.M. Nieschlag E. (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82: 2386–2390.
10. Binkley N. Adler R.A. (2010) Dual-energy X-ray absorptiometry (DXA) in men, In: Ed. Orwoll E.S. Bilezikian J.P. Vanderschueren D. (eds). Osteoporosis in Men, 2nd ed, Academic Press: New York, pp. 525–540.
11. Binkley N. Krueger D. Cowgill C.S. Plum L. Lake E. Hansen K.E. et al (2004) Assay variation confounds the diagnosis of hypovitaminosis D: A call for standardization. J Clin Endocrinol Metab 89: 3152–3157.
12. Binkley N. Krueger D. Lensmeyer G. (2009) 25-hydroxyvitamin D measurement 2009; a review for clinicians. J Clin Densitom 12: 417–427.
13. Black D.M. Schwartz A.V. Ensrud K.E. Cauley J.A. Levis S. Quandt S.A. et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927–2938.
14. Bleicher K. Cumming R.G. Naganathan V. Seibel M.J. Sambrook P.N. Blyth F.M. et al (2010) Lifestyle factors, medications, and disease influence bone mineral density in older men: Findings from the CHAMP study. Osteoporos Int, in press.
15. Bolland M.J. Avenell A. Baron J.A. Grey A. MacLennan G.S. Gamble G.D. et al (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: Meta-analysis. BMJ 341: c3691.
16. Boonen S. Orwoll E.S. Wenderoth D. Stoner K.J. Eusebio R. Delmas P.D. (2009) Once-weekly risedronate in men with osteoporosis: Results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24: 719–725.
17. Boonen S. Sellmeyer D.E. Lippuner K. Orlov-Morozov A. Abrams K. Mesenbrink P. et al (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74: 641–648.
18. Burge R. Dawson-Hughes B. Solomon D.H. Wong J.B. King A. Tosteson A. (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22: 465–475.
19. Cauley J.A. Ewing S.K. Taylor B.C. Fink H.A. Ensrud K.E. Bauer D.C. et al (2010) Sex steroid hormones in older men: Longitudinal associations with 4.5-year change in hip bone mineral density – the osteoporosis fractures in men study. J Clin Endocrinol Metab 95: 4314–4323.
20. Chaganti R.K. Parimi N. Lang T. Orwoll E. Stefanick M.L. Nevitt M. et al (2010) Bone mineral density and prevalent osteoarthritis of the hip in older men for the Osteoporotic Fractures in Men (MrOS) Study Group. Osteoporos Int 21: 1307–1316.
21. Deutschmann H.A. Weger M. Weger W. Kotanko P. Deutschmann M.J. Skrabal F. (2002) Search for occult secondary osteoporosis: Impact of identified possible risk factors on bone mineral density. J Intern Med 252: 389–397.
22. Feldstein A.C. Nichols G. Orwoll E. Elmer P.J. Smith D.H. Herson M. et al (2005) The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 16: 953–962.
23. Finkelstein J.S. Klibanski A. Neer R. (1996) A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab 81: 1152–1155.
24. Hansen K.E. Swenson E.D. Baltz B. Schuna A.A. Jones A.N. Elliott M.E. (2008) Adherence to alendronate in male veterans. Osteoporos Int 19: 349–356.
25. Heaney R.P. Holick M.F. (2011) Why the IOM recommendations are deficient. J Bone Miner Res 26: 455–457.
26. Ishijima M. Sakamoto Y. Yamanaka M. Tokita A. Kitahara K. Kaneko H. et al (2009) Minimum required vitamin D level for optimal increase in bone mineral density with alendronate in osteoporotic women. Calcif Tissue Int 85: 398–404.
27. Jackson R.D. LaCroix A.Z. Gass M. Wallace R.B. Robbins J. Lewis C.E. et al (2006) Calcium plus vitamin D supplementation and the risk of fracture. N Engl J Med 354: 669–683.
28. Kanis J.A. Johansson H. Oden A. Dawson-Hughes B. Melton L.J. III McCloskey E.V. (2010) The effects of a FRAX revision for the USA. Osteoporos Int 21: 35–40.
29. Kannegaard P.N. van der Mark S. Eiken P. Abrahamsen B. (2010) Excess mortality in men compared with women following a hip fracture: National analysis of comedications, comorbidity, and survival. Age Ageing 39: 203–209.
30. Kasturi G.C. Adler R.A. (2011) Osteoporosis: nonpharmacologic management. (in press).
31. Kaufman J.M. Orwoll E. Goemaere S. San Martin J. Hossain A. Dalsky G.P. et al (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy. Osteoporos Int 16: 510–516.
32. Khosla S. Burr D. Cauley J. Dempster D.W. Ebeling P.R. Felsenberg D. et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479–1491.
33. Khosla S. Melton L.J. III Atkinson E.J. O'Fallon W.M. Klee C.G. Riggs B.L. (1998) Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 82: 2386–2390.
34. Kurland E.S. Cosman F. McMahon D.J. Rosen C.J. Lindsay R. Bilezikian J.P. (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85: 3069–3076.
35. Kurland E.S. Heller S.L. Diamond B. McMahon D.J. Cosman F. Bilezikian J.P. (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1–34)]. Osteoporos Int 15: 992–997.
36. Lewis J.R. Calver J. Zhu K. Flicker L. Prince R.L. (2011) Calcium supplementation and the risks of atherosclerotic vascular disease in older women: Results of a 5-year RCT and a 4.5 year follow-up. J Bone Miner Res 26: 35–41.
37. Lim L.S. Hoeksema L.J. Sherin, K. for the ACPM Prevention Practice Committee (2009) Screening for osteoporosis in the adult US population. Am J Prev Med 36: 366–375.
38. Lyles K.W. Colon-Emeric C.S. Magaziner J.S. Adachi J.D. Peiper C.F. Mautalen C. et al (2007) Zoledronic acid in reducing clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799–1809.
39. McKiernan F.E. Berg R.L. Linneman J.G. (2010) The utility of BMD Z-score diagnostic thresholds for secondary causes of osteoporosis. Osteoporos Int, in press.
40. Miller P.D. Roux C. Boonen S. Barton I.P. Dunlap L.E. Burgio D.E. (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res 20: 2105–2115.
41. Neer R.M. Arnaud C.D. Zanchetta J.R. Prince R. Gaich G.A. Reginster J.Y. et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441.
42. Nguyen N.D. Frost S.A. Center J.R. Eisman J.A. Nguyen T.V. (2008) Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 18: 1109–1117.
43. Orwoll E. Ettinger M. Weiss S. Miller P. Kendler D. Graham J. et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: 604–610.
44. Orwoll E. Miller P. Adachi J. Brown J. Adler R.A. Kendler D. et al (2010) Efficacy and safety of once-yearly i.v. infusion of zoledronic acid 5 mg versus once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, doubleblind, active-controlled study. J Bone Miner Res 25: 2239–2250.
45. Orwoll E.S. Scheele W.H. Paul S. Adami S. Syversen U. Diez-Perez A. et al (2003) The effects of teriparatide [human parathyroid hormone (1–34) therapy on bone density in men with osteoporosis. J Bone Miner Res 18: 9–17.
46. Painter S.E. Kleerekoper M. Camacho P.M. (2006) Secondary osteoporosis: A review of the recent evidence. Endocr Pract 12: 436–445.
47. Papaioannou A. Kennedy C.C. Cranney A. Hawker G. Brown J.P. Kaiser S.M. et al (2009) Risk factors for low BMD in healthy men age 50 years or older: A systematic review. Osteoporosis Int 20: 507–518.
48. Patrick A.R. Brookhart M.A. Losina E. Schousboe J.T. Cadarette S.M. Mogun H. et al (2010) The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab 95: 3251–3259.
49. Pearce G. Tabensky D.A. Delmas P.D. Baker H.W. Seeman E. (1998) Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 83: 801–806.
50. Priemel M. von Domarus C. Klatte T.O. Kessler S. Schlie J. Meier S. et al (2010) Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 25: 305–312.
51. Qaseem A. Snow V. Shekelle P. (2008) Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians. Ann Intern Med 148: 680–684.
52. Ringe J.D. Dorst A. Farahmand P. (2010) Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung 60: 267–272.
53. Rizzoli R. Akesson K. Bouxsein M. Kanis J.A. Napoli N. Papapoulos S. et al (2011) Subtrochanteric fractures after long-term treatment with bisphosphonates: A European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 22: 373–390.
54. Rosen C.J. (2011) Vitamin D insufficiency. N Engl J Med 364: 248–254.
55. Rosen C.J. Kurland E.S. Vereault D. Adler R.A. Rackoff P.J. Craig W.Y. et al (1998) An association between serum IGF-I and a simple sequence repeat in the IGF-I gene: Implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 83: 2286–2290.
56. Ross A.C. Manson J.E. Abrams S.A. Aloia J.F. Brannon P.M. Clinton S.K. et al (2011) The 2011 report of dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 96: 53–58.
57. Ryan C.A. Petkov V.I. Adler R.A. (2011) Osteoporosis in men: The value of laboratory testing. Osteoporos Int 22: 1845–1853.
58. Sandhu S.K. Nguyen N.D. Center J.R. Pocock N.A. Eisman J.A. Nguyen T.V. (2010) Prognosis of fracture: Evaluation of predictive accuracy of the FRAXTM algorithm and Garvan nomogram. Osteoporos Int 21: 863–871.
59. Sato Y. Iwamoto J. Kanoko T. Satoh K. (2005) Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165: 1743–1748.
60. Schousboe J.T. Vokes T. Broy S.B. Ferrar L. McKiernan F. Roux C. et al (2008) Vertebral fracture assessment: The 2007 ISCD official positions. J Clin Densitom 11: 92–108.
61. Shane E. Burr D. Ebeling P.R. Abrahamsen B. Adler R.A. Brown T.D. et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25: 2267–2294.
62. Shaninian V.B. Kuo Y.-F. Freeman J.L. Goodwin J.S. (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352: 2386–2390.
63. Smith M.R. Egerdie B. Toriz N.H. (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361: 756–765.
64. Tosteson A. Melton L.J. III Dawson-Hughes B. Baim S. Favus M.J. Khosla S. et al (2008) Cost-effective osteoporosis treatment thresholds: The United States perspective. Osteoporos Int 19: 437–447.
65. Trimpou P. Landin-Wilhelmsen K. Oden A. Rosengren A. Wilhelmsen L. (2010) Male risk factors for hip fracture in a 30-year follow-up study in 7,495 men. Osteoporos Int 21: 409–416.
66. Preventive Services Task Force, US (2011) Screening for osteoporosis: Preventive Services Task Force recommendation statement. Ann Intern Med, in press.
67. van Potelbergh I. Goemaere S. Zmierczak H. Kaufman J.M. (2004) Perturbed sex steroid status in men with idiopathic osteoporosis and their sons. J Clin Endocrinol Metab 89: 4949–4953.
68. van Staa T.P. Leufkens H.G. Abenhaim L. Zhang B. Cooper C. (2000) Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatology (Oxford) 39: 1383–1389.
69. Vestergaard P. Schwartz F. Renjmark L. Mosekilde L. (2011) Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int 22: 993–1001.